CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 20, 2020--
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at Biocom’s 10th Annual Global Life Sciences Partnering Conference on February 27, 2020 at 2:30pm Pacific Time at the Lodge at Torrey Pines, La Jolla, CA.
In its 10th year, the 2020 Biocom Global Life Science Partnering Conference is an exclusive partnering forum that provides senior executives, bankers, venture capitalists, and business development professionals from the leading pharmaceutical and biotech companies to network and do business with one another from around the globe. This annual biopharma partnering conference brings together leading deal makers and emerging biotechs from around the world, while providing a local San Diego venue to showcase the impressive accomplishments and progress taking place in one of the top biotech hubs in the world. Interested parties may follow @BiocomCA on Twitter for the latest conference updates.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005142/en/
Source: Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa